Altimmune, Inc. (NASDAQ:ALT) Q3 2023 Earnings Conference Call November 7, 2023 8:30 AM ET

Company Participants

Rich Eisenstadt - Chief Financial Officer

Vipin Garg - Chief Executive Officer

Scott Harris - Chief Medical Officer

Scot Roberts - Chief Scientific Officer

Conference Call Participants

Yasmeen Rahimi - Piper Sandler

Roger Song - Jefferies

William Wood - B. Riley

Jonathan Wolleben - JMP Securities

Louis Susser - H. C. Wainwright

Operator

Good day, ladies and gentlemen, and welcome to the Altimmune, Inc. Third Quarter 2023 Financial Results Conference Call. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session, and instructions will follow at that time. [Operator Instructions] As a reminder, this call is being recorded.

I would now like to introduce your host for today's conference call, Rich Eisenstadt, Chief Financial Officer of Altimmune. Rich, you may begin.

Rich Eisenstadt

Thank you, Olivia, and good morning, everyone. Thank you for participating in Altimmune's third quarter 2023 financial results and business update conference call. Members of the Altimmune team joining me on the call today are Vipin Garg, our Chief Executive Officer; Scot Roberts, our Chief Scientific Officer; and Scott Harris, our Chief Medical Officer.

Following the prepared remarks, we will hold a question-and-answer session. A press release with our third quarter 2023 financial results was issued this morning and could be found on the Investor Relations section of the company's website.

Before we begin, I'd like to remind everyone that remarks about future expectations, plans and prospects constitute forward-looking statements for purposes of Safe Harbor provisions under the Private Securities Litigation Reform Act of 1995. Altimmune cautions that these forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those indicated.

For a discussion of some of the risks and factors that could affect the company's future results and operations, please see the risk factors and other cautionary statements contained in the company's filings with the SEC.

I would also direct you to read the forward-looking statement disclosure in our press release issued this morning, and now available on our website. Any statements made on this conference call speak only as of today's date, Tuesday, November 7, 2023, and the company does not undertake any obligation to update any of these forward-looking statements to reflect events or circumstances that occur on or after today's date. As a reminder, this conference call is being recorded and will be available for audio replay on Altimmune's website.